CannabisNewsBreaks – India Globalization Capital (NYSE: IGC) Avoids Regulatory Costs through Cannabis-based Drug Candidates

India Globalization Capital (NYSE AMERICAN: IGC) is developing a portfolio of products using cannabis-based “combination therapies” for the treatment of various life-altering conditions. The company is employing a distinctive strategy to bring these drug candidates to market. An article discussing this reads: “IGC’s unique strategy reduces regulatory approval time and development costs because its chosen categories face lower regulatory burdens. Instead of pursuing full novel drug applications, which take anywhere from 7-9 years in clinical trials and cost hundreds of millions before securing FDA approval, IGC is developing cannabis-based drugs that could be commercialized in less than two years and at a cost of between $2 million and $3 million per product. These products will then be made available through medical cannabis dispensaries, which means a faster development timeline with a much lower end cost than through the traditional pharmaceutical pipeline.”

To view the full article, visit

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information, visit the company’s website at

More from CannabisNewsBreaks

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published:

CannabisNewsWire (CNW)
Denver, Colorado
303.498.7722 Office

Leave a Reply